Overview A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis Status: NOT_YET_RECRUITING Trial end date: 2026-11-06 Target enrollment: Participant gender: Summary The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.Phase: PHASE2 Details Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.